Today: Today, Aclaris Therapeutics Inc. (ACRS) Receives New Coverage from Analysts at Leerink Swann

Today, Aclaris Therapeutics Inc. (ACRS) Receives New Coverage from Analysts at Leerink Swann

Research analysts at Leerink Swann assumed coverage on shares of Aclaris Therapeutics Inc. (NASDAQ:ACRS) in a note issued to investors on Tuesday. The brokerage set an “outperform” rating on the stock.

Several other research analysts have also recently issued reports on ACRS. Zacks Investment Research raised Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, October 18th. Jefferies Group reaffirmed a “buy” rating and set a $32.00 price objective (up from $29.00) on shares of Aclaris Therapeutics in a research report on Friday, November 18th. Finally, JMP Securities began coverage on Aclaris Therapeutics in a research report on Friday, September 30th. They set an “outperform” rating and a $34.00 price objective for the company. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $32.50.

Shares of Aclaris Therapeutics (NASDAQ:ACRS) traded up 4.6009% on Tuesday, reaching $29.3301. The company had a trading volume of 52,635 shares. The firm’s market capitalization is $628.60 million. Aclaris Therapeutics has a 52 week low of $14.12 and a 52 week high of $33.88. The company’s 50-day moving average price is $23.20 and its 200 day moving average price is $21.47.

Aclaris Therapeutics (NASDAQ:ACRS) last released its quarterly earnings data on Thursday, November 3rd. The company reported ($0.50) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.66) by $0.16. On average, analysts expect that Aclaris Therapeutics will post ($2.38) EPS for the current year.

In other Aclaris Therapeutics news, major shareholder Ventures Fund Vii L.P. Vivo sold 907,828 shares of the company’s stock in a transaction that occurred on Friday, November 18th. The stock was sold at an average price of $23.03, for a total transaction of $20,907,278.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Ra Capital Management, Llc sold 525,550 shares of the company’s stock in a transaction that occurred on Friday, September 16th. The shares were sold at an average price of $24.19, for a total value of $12,713,054.50. The disclosure for this sale can be found here. 46.40% of the stock is owned by corporate insiders.

Hedge funds have recently bought and sold shares of the stock. BlackRock Institutional Trust Company N.A. increased its stake in Aclaris Therapeutics by 150.8% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 70,930 shares of the company’s stock valued at $1,310,000 after buying an additional 42,644 shares in the last quarter. BlackRock Fund Advisors increased its stake in Aclaris Therapeutics by 59.7% in the second quarter. BlackRock Fund Advisors now owns 234,696 shares of the company’s stock valued at $4,335,000 after buying an additional 87,739 shares in the last quarter. BlackRock Investment Management LLC increased its stake in Aclaris Therapeutics by 67.3% in the second quarter. BlackRock Investment Management LLC now owns 34,153 shares of the company’s stock valued at $631,000 after buying an additional 13,734 shares in the last quarter. Vanguard Group Inc. increased its stake in Aclaris Therapeutics by 147.6% in the second quarter. Vanguard Group Inc. now owns 419,184 shares of the company’s stock valued at $7,743,000 after buying an additional 249,888 shares in the last quarter. Finally, Nationwide Fund Advisors increased its stake in Aclaris Therapeutics by 47.0% in the second quarter. Nationwide Fund Advisors now owns 5,747 shares of the company’s stock valued at $106,000 after buying an additional 1,838 shares in the last quarter. 72.10% of the stock is owned by hedge funds and other institutional investors.

Aclaris Therapeutics Company Profile

Related posts

Leave a Comment